Skip to main content
  • P2Y12 Inhibitors Show No Significant Effect in Non-Critically Ill, Hospitalized COVID-19 Patients

    In patients hospitalized with COVID-19 who were not critically ill, the use of P2Y12 inhibitors did not meaningfully increase the number of days alive or reduce the need for cardiovascular or respiratory organ support, according to new study data.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details